Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9277742 | 0.98 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3EPHX2OPRM1 | |
| Hydrochloric Acid SCHEMBL9277740 | 0.98 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3EPHX2OPRM1 | |
| SCHEMBL21503662 | 0.82 | FFAR4 (0.34) | SLC6A2SLC6A4SLC6A3KDM1AROCK1 | |
| Hydrochloric Acid SCHEMBL21491663 | 0.80 | FFAR4 (0.34) | SLC6A2SLC6A4SLC6A3KDM1AROCK1 | |
| Hydrochloric Acid SCHEMBL21491660 | 0.80 | FFAR4 (0.34) | SLC6A2SLC6A4SLC6A3KDM1AROCK1 | |
| SCHEMBL23951609 | 0.79 | KDM1A (0.42) | SLC6A2SLC6A4SLC6A3EPHX2GRIN1 | |
| SCHEMBL26933091 | 0.79 | FFAR4 (0.34) | SLC6A2SLC6A4SLC6A3KDM1A | |
| SCHEMBL26933086 | 0.79 | FFAR4 (0.34) | SLC6A2SLC6A4SLC6A3KDM1A | |
| SCHEMBL3037790 | 0.78 | EPHX2 (0.48) | SLC6A2SLC6A4SLC6A3EPHX2OPRM1 | |
| Hydrochloric Acid SCHEMBL23924284 | 0.78 | KDM1A (0.44) | SLC6A2SLC6A4SLC6A3EPHX2GRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4313951-A1 | 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2024-02-07 | — | — | EP | disclosed |
| US-11845730-B2 | 1,3-substituted cyclobutyl derivatives and uses thereof | CITIBANK, N.A., AS NOTES COLLATERAL AGENT | 2023-12-19 | — | — | US | disclosed |
| WO-2012072512-A1 | N-CYCLOBUTYL-IMIDAZOPYRIDINE OR -PYRAZOLOPYRIDINE CARBOXAMIDES AS TRPV1 ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2012-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11845730-B2 | 1,3-substituted cyclobutyl derivatives and uses thereof | TRPV1, TRPV3, TRPV2 | SLC6A2 2286/4885SLC6A4 1408/4885SLC6A3 2001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.